Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Eli Lilly & Co.'s SEC filings document the regulatory record for its pharmaceutical business, listed common stock and NYSE-traded notes. Forms 8-K report operating results and financial condition, annual meeting vote outcomes, director and officer matters, underwriting agreements and other material events tied to the company's capital structure and governance.
Proxy filings provide formal disclosure on board elections, executive compensation, shareholder voting matters and pay-versus-performance information. The company's exchange-listed securities include no-par common stock under LLY and multiple series of notes with maturities extending across its debt capital structure.
Eli Lilly (LLY) reported an insider transaction: the company’s SVP, Finance, & CAO sold 1,000 shares of common stock at $1,010.50 per share on November 13, 2025 (transaction code S).
The filing states the trade was made under a Rule 10b5-1 trading plan adopted on November 20, 2024. Following the sale, the reporting person beneficially owns 2,839.659 shares directly and 1,727.9 shares indirectly through a 401(k).
Eli Lilly (LLY) reported insider activity on a Form 4 showing multiple open‑market sales of common stock on 11/12/2025. The transactions were executed in several tranches at weighted‑average prices disclosed in footnotes.
Following the reported sales, the reporting person beneficially owned 93,106,978 shares, held directly. Footnotes note the sales occurred across price ranges from $1,001.213 to $1,021.661, with the reporting person able to provide detailed trade breakdowns upon request.
Lilly Endowment Inc. filed a Form 144 notice to sell 295,000 shares of Eli Lilly and Company (LLY) common stock. The filing lists an aggregate market value $300,245,100, an approximate sale date of November 13, 2025, execution through Fidelity Capital Markets, and trading on NYSE, NASDAQ.
The filing notes that 945,383,757 shares of Eli Lilly common stock are outstanding. The securities to be sold trace back to a gift acquired on 02/10/1948 from the J.K. Lilly Sr. Trust, with the donor’s acquisition dated 01/21/1937 and an original amount acquired of 38,400,000 shares.
Recent sales over the past three months are disclosed, including 305,000 shares for $308,411,211.50 on 11/12/2025 and 283,131 shares for $279,347,662.01 on 11/11/2025.
Eli Lilly (LLY): Insider transaction reported. A reporting person filed a Form 4 disclosing multiple open‑market sales of Eli Lilly common stock on November 11, 2025. Each line item is coded “S” for sale and reflects a weighted average price, with individual trades occurring within the disclosed ranges.
Reported weighted average prices spanned approximately $972.269 to $999.088, with footnotes stating underlying trade ranges from $972.00 to $999.49 per share across the listed transactions. Following these sales, the reporting person beneficially owned 93,411,978 shares, held directly.
Eli Lilly & Co (LLY) reported insider transactions on 11/10/2025. The reporting person executed three open-market sales: 12,864 shares at a weighted average price of $972.168 (range $972.00–$972.87); 3,887 shares at $973.626 (range $973.025–$973.95); and 118 shares at $974.089 (range $974.065–$974.14).
After these transactions, the reporting person beneficially owned 93,695,109 shares, held directly.
Lilly Endowment Inc. filed a Form 144 to sell 305,000 shares of Eli Lilly and Company (LLY) common stock, with an approximate sale date of November 12, 2025. The designated broker is J.P. Morgan Securities LLC, and the filing lists NYSE, NASDAQ as the exchanges.
The notice also details recent activity: examples include 300,000 shares sold on November 3, 2025 for $266,648,940 and 283,131 shares sold on November 11, 2025 for $279,347,662.01. The shares to be sold trace back to an earlier acquisition noted as a gift dated February 10, 1948 from the J.K. Lilly Sr. Trust.
Eli Lilly (LLY) CEO David A. Ricks reported a code G transfer of 24,750 shares of common stock on 11/10/2025 at a stated price of $0. Following the transaction, he directly owns 515,166.167 shares.
He also reports indirect holdings, including 6,685 shares by the David A. Ricks 2025 GRAT, 54,117 shares by the 2022 GRAT, 300 shares by a trust, 68,656 shares by the David A. Ricks SLAT, and 7,305.09 shares in a 401(k). The footnotes note a transfer of 6,685 shares to the 2025 GRAT on September 9, 2025.
Eli Lilly (LLY) officer (EVP, CS&PO & Pres. LRL) reported a Code G transaction of 179 shares of common stock on 11/10/2025 at a reported price of $0.
Following the transaction, the officer beneficially owned 137,481.112 shares directly. Indirect holdings were reported as 72,359 shares by a trust, 547 shares by a spouse, and 2,710 shares by a spouse’s SLAT, subject to a standard pecuniary interest disclaimer.
The filing notes a 200‑share correction to reconcile these holdings with a submission filed on August 12, 2025.
Lilly Endowment Inc. filed a Form 144 indicating a proposed sale of 300,000 shares of Eli Lilly and Company common stock, with an aggregate market value of $277,311,000. The filing lists Fidelity Capital Markets as broker, an approximate sale date of 11/10/2025, and the securities exchange as NYSE, NASDAQ.
The shares to be sold were originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust (donor acquisition date 01/21/1937). The notice also reports recent sales by Lilly Endowment Inc. over the past three months, including 300,000 shares on 11/03/2025 for $266,648,940 and 351,015 shares on 10/01/2025 for $284,653,451.48.
Eli Lilly, through its wholly owned subsidiary Flying Tigers Acquisition Corporation, launched a cash tender offer to acquire all outstanding shares of Adverum Biotechnologies (ADVM). Holders who tender will receive $3.56 per share in cash, plus one non‑tradable contingent value right (CVR) per share that entitles the holder to receive up to an aggregate $8.91 in contingent cash payments upon achievement of specified milestones, all subject to the terms and conditions of the CVR agreement and the Offer to Purchase.
The consideration is payable in cash, without interest and less applicable tax withholding, and the CVR provides potential added payments tied to future milestone achievements.
Eli Lilly, through its wholly owned subsidiary Flying Tigers Acquisition Corporation, launched a cash tender offer to acquire all outstanding shares of Adverum Biotechnologies (ADVM). Holders who tender will receive $3.56 per share in cash, plus one non‑tradable contingent value right (CVR) per share that entitles the holder to receive up to an aggregate $8.91 in contingent cash payments upon achievement of specified milestones, all subject to the terms and conditions of the CVR agreement and the Offer to Purchase.
The consideration is payable in cash, without interest and less applicable tax withholding, and the CVR provides potential added payments tied to future milestone achievements.